ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / OPK
SLN (44) SNDX (17) RAPP (30) LBRX (39) ⌘ Pro Terminal →

OPKO Health Inc. (OPK) — RQD Stock Rating Cockpit

$1.72 +3.61% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.73

OPKO Health Inc. (OPK) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $1.24B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on OPK Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is OPK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, OPKO Health Inc. (NASDAQ: OPK) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $1.72 (+3.61% 1D, market cap $1.24B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, OPK ranks #457 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does OPK compare to SLN and SNDX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OPK carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 33.9%, and ROIC of -10.2%. By comparison, SLN (Silence Therapeutics Plc American Depository Share) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $1.23B) and SNDX (Syndax Pharmaceuticals Inc.) posts a E grade (17/100 RQD, P/E N/A, ROIC -35.0%, cap $1.22B). Among the 5-stock peer group, OPK leads on earnings multiple (N/A) while LBRX leads on capital efficiency (-8.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for OPK?
▼

Per OPK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000944809), OPKO Health Inc. generated $606.9M in revenue (-14.9% YoY), -$225.68B in net income, and -$178.5M in free cash flow against $1.93B in total assets and $2.3M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.73 (+0.46%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510040
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Cash (5)Whales (14)SEC (8)Macro (10)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-8.1% Base Target
$2 Bull$2 Base$1 Bear
📬 FREE OPK RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OPK)Realized 20D OHLCV Swing Band: ±10.7%
Deterministic 5-Pillar Attribution (40/100 Composite)
🔍 WHY OPK SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (35% of score)

20D Institutional Volume Accumulation (±10.7% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (25% of score)

FRED Regime × Technicals: 94% of 52W Range • RSI-14 at 58.9 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
32
Grade E$1.32+25.8% Next Q
Q2 (-2Q)
35
Grade E$1.66-3% Next Q
Q3 (-1Q)
37
Grade E$1.61+6.8% Next Q
Current
40
Grade D-$1.72-7.4% Hist 90D α
Trajectory: E (32) → D- (40)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a OPK Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While OPK currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.57) and Max Pain ($1.81) forces dealer call-delta covering toward $1.86.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $OPK• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “OPK Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 40%NO 60%Trade / Inspect Odds →
RSI-14 MOMENTUMBULLISH MOMENTUM
58.930 Oversold · 70 Hot
ALTMAN-Z SHIELDDISTRESS RISK (<1.8)
0.20>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
4 / 99-Pt Accounting
52-WEEK LASER RANGE94% OF RANGE
L: $1$1.72H: $2
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 5 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 17 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 18 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on OPK

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (25)

-10.2% ROIC with 33.9% gross margin and -14.41% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (40)

Altman-Z 0.20 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (45)

17/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like OPK
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OPK)

  • ✓Walkthrough of OPK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
OPK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +54.95%▲ ASCENDING CHANNEL
2026-11-03O $1.66H $1.72L $1.66C $1.72VOL 2.15M
RES: $1.79SUP: $1.33SMA50: $1.57SMA200: $1.35
$1.82$1.62$1.42$1.22$1.02RES $1.79SUP $1.33$1.722026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OPK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 OPK Butterfly Map → + Track OPK →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -14.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on OPK today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for OPK. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for OPK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OPK)

Health Care Rank #457 of 1015 ⚔️ SLN vs OPK Full Matrix →

1. Head-to-Head Health Care Peer Comparison (OPK vs. SLN, SNDX, RAPP, LBRX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, OPKO Health Inc. (OPK) ranks #457 by composite RQD confidence (40/100, grade D-) and #327 by equity capitalization ($1.24B). Within this direct 5-issuer industry benchmark cohort, OPK leads on earnings valuation at N/A trailing P/E, while LBRX leads on capital efficiency and profitability with -8.4% ROIC and — gross margin. SLN currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with OPK at 40/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
OPK ACTIVE
OPKO Health Inc.
D- 40/100 — 33.9% -10.2% +3.61% $1.24B Benchmark Subject
SLN
Silence Therapeutics Plc American Depository Share
D 44/100 — 61.5% -35.0% +0.05% $1.23B /sln-vs-opk →
SNDX
Syndax Pharmaceuticals Inc.
E 17/100 — — -35.0% -4.03% $1.22B /sndx-vs-opk →
RAPP
Rapport Therapeutics Inc.
E 30/100 — — -22.9% +0.32% $1.20B /rapp-vs-opk →
LBRX
LB Pharmaceuticals Inc
D- 39/100 — — -8.4% -1.66% $1.28B /lbrx-vs-opk →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000944809 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), OPKO Health Inc. (OPK) reported GAAP revenue of $606.9M (-14.9% vs. FY2024 revenue of $713.1M , and -29.7% cumulative change since FY2023) , GAAP net income of -$225.68B, operating cash flow of -$178.5M, and free cash flow of -$178.5M (+2.7% YoY). On the balance sheet, OPK closed FY2025 with $1.93B in total assets against $2.3M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $606.9M -$225.68B -$178.5M -$178.5M $1.93B $2.3M
FY2024 (FY) 2024-12-31 $713.1M -$53.22B -$183.5M -$183.5M $2.20B $3.0M
FY2023 (FY) 2023-12-31 $863.5M -$188.86B -$28.2M -$28.2M — —

3. OPK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OPK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, OPKO Health Inc. (NASDAQ: OPK) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $1.72 (+3.61% 1D, market cap $1.24B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, OPK ranks #457 in composite RQD confidence.

How does OPK compare to SLN and SNDX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OPK carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 33.9%, and ROIC of -10.2%. By comparison, SLN (Silence Therapeutics Plc American Depository Share) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $1.23B) and SNDX (Syndax Pharmaceuticals Inc.) posts a E grade (17/100 RQD, P/E N/A, ROIC -35.0%, cap $1.22B). Among the 5-stock peer group, OPK leads on earnings multiple (N/A) while LBRX leads on capital efficiency (-8.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for OPK?

Per OPK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000944809), OPKO Health Inc. generated $606.9M in revenue (-14.9% YoY), -$225.68B in net income, and -$178.5M in free cash flow against $1.93B in total assets and $2.3M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is OPK trading relative to its 50-day, 200-day, and 52-week technical levels?

OPK last traded at $1.72 (+3.61% on volume of 3,081,730 shares), positioning the stock +9.55% above its 50-day simple moving average ($1.57) and +27.41% above its 200-day simple moving average ($1.35). Across its 52-week range of $0.98 to $1.77, OPK sits at the 93.7% percentile with a 14-day RSI of 58.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±10.7% ($1.54 to $1.90).

Direct Sub-Reports: OPK RQD Cockpit OPK 12M Forecast OPK Earnings & Move OPK Dividends & DRIP OPK Insiders & 13F OPK Whale Options OPK Profit Sankey OPK News & Why
ROARABLE RATING BRIEF • RQD 40/100 (D-) ✓ SEC XBRL & RQD VERIFIED

OPK — OPKO Health Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

OPKO Health Inc. (OPK) earns a live Roarable RQD composite score of 40/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $1.72 (+3.61% 1D, market capitalization $1.24B).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -10.2%, gross margin of 33.9%, operating margin of -19.3%, and free cash flow yield of -14.41%.
  • Whale 13F & Options Flow (14/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 4/9, and Debt/Equity of 0.00x.

2. Business Model, Unit Margins & SEC Financial Trajectory

. (OPK) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Per the market data, it reports a gross margin of 33.9%, indicating that product-level revenue is retained after direct costs. — regarding specific products, customers, or revenue model details.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), OPKO Health Inc. (OPK) reported $606.9M in annual revenue (up from $713.1M in FY2024, -14.9% YoY) and -$225.68B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($863.5M revenue, -$188.86B net income) through FY2025, OPK scaled operating cash flow to -$178.5M and free cash flow to -$178.5M, backed by $1.93B in total assets against $2.3M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 40/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -14.41% and institutional whale pillar of 14/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 14/20, sustained execution supports upside toward the upper end of the $0.98 – $1.77 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -19.3% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are — The only cross-entity reference in the news flow is to Labcorp Holdings (NYSE:LH) in the Benzinga headline, which is a counterparty to the asset-sale report and not a documented supply-chain link.

  • Key Question #1: Can OPK sustain or expand its -19.3% operating margin and -10.2% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $606.9M and free cash flow of -$178.5M, how will capital allocation balance growth reinvestment against $2.3M in total debt?
  • Key Question #3: How sensitive is OPK's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

OPK Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for OPKO Health Inc. (OPK) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to OPK Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

OPK Bull vs. Bear Conversation Board — What's Your Call at $1.72?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON OPK 🐻 33% BEARISH CONVICTION
1. Pick Your Side on OPK:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $1.91 (+15.1%)
📌 Pinned Debate

Institutional accumulation (14/20 whale flow pillar) and the Labcorp asset-sale catalyst offer a potential recovery path.

Institutional accumulation (14/20 whale flow pillar) and the Labcorp asset-sale catalyst offer a potential recovery path.. When you look under the hood at OPK, Fundamental Cash Engine is 5/20 with 33.9% gross margins and -10.2% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (14/20) has been quietly accumulating below $1.77. My 12M target is $1.91.

ArenaChamp_24 🐂 BULL

@MidwestValue Agree on the RQD 40/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.66 and keeping dry powder in case we test $1.54.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $1.38 (-16.9%)
Spot @ $1.66

Negative ROIC of -10.2%, FCF yield of -14.41%, and an Altman Z of 0.2 signal a weak cash engine and fragile balance sheet.

Careful chasing OPK at $1.66. Negative ROIC of -10.2%, FCF yield of -14.41%, and an Altman Z of 0.2 signal a weak cash engine and fragile balance sheet.. Gross margin is 33.9%, but operating margin is -19.3%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $1.38 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%